Results 71 to 80 of about 19,221 (177)

Integrating the inputs that shape pancreatic islet hormone release. [PDF]

, 2019
The pancreatic islet is a complex mini organ composed of a variety of endocrine cells and their support cells, which together tightly control blood glucose homeostasis.
Huising, Mark O, Noguchi, Glyn M
core  

Metabolic effects of secretin [PDF]

, 2013
postprin
Chow, BKC, Sekar, R
core   +1 more source

Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima, Hideyoshi Kaga, Naoaki Ito, Toshiki Kogai, Hitoshi Naito, Saori Kakehi, Satoshi Kadowaki, Yuya Nishida, Ryuzo Kawamori, Yoshifumi Tamura, Hirotaka Watada   +10 more
wiley   +1 more source

Regulation of Insulin Secretion Through Long‐Chain Fatty Acid Receptors

iNew Medicine, EarlyView.
Stefan Offermanns
wiley   +1 more source

Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay, Jason Hom, Tamara Scott, Neera Ahuja   +3 more
wiley   +1 more source

The evolution of the therapeutic concept ‘GIP receptor antagonism’

Frontiers in Endocrinology
Glucose-dependent insulinotropic polypeptide (GIP) is an intestinal hormone that potentiates glucose-induced insulin secretion in the postprandial state. GIP exerts a broad range of other physiological actions e.g.
Frederikke Koefoed-Hansen, Frederikke Koefoed-Hansen, Mads Marstrand Helsted, Hüsün Sheyma Kizilkaya, Asger Bach Lund, Asger Bach Lund, Asger Bach Lund, Mette Marie Rosenkilde, Lærke Smidt Gasbjerg, Lærke Smidt Gasbjerg   +9 more
doaj   +1 more source

What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters [PDF]

, 2016
Diabetes Mellitus (DM) is a syndrome caused by various etiologies. The clinical manifestations of DM are not indicative of the cause of the disease, but might be indicative of the stage and severity of the disease process.
Abdul-Rasoul, Agarwal, Ahlgren, Alejandro, American Diabetes Association, Anderson, Appleton, Atkins, Atkins, Batchelor, Belle, Bostrom, Brackeva, Brenner, Butler, Catchpole, Catchpole, Chiang, Concannon, Coppieters, Cui, Das, Davison, Davison, Davison, De Cock, Eigenmann, Fajans, Fall, Forcada, Forcada, Forsberg, Furrer, Gepts, Gilor, Gilor, Gilor, Girman, Goossens, Gostelow, Gottlieb, Guptill, Haines, Hall, Herold, Hess, Hewson-Hughes, Hoenig, Hoenig, Hoffmann, Holst, Hume, Imamura, Jensen, Kappe, Kennedy, Kenny, Kilpatrick, Kim, Kitamura, Klupa, Kramer, Kramer, Lem, Ling, Link, Lutz, Mattin, McDonald, Miceli, Michels, Neiger, Nelson, Nelson, Niessen, Niessen, Nishii, Orban, Panciera, Papa, Pietropaolo, Porte, Porte, Prahl, Prasad, Rand, Ranta, Reaven, Russell-Jones, Safra, Scudder, Shields, Slingerland, Solanki, Strage, Sun, Temple, Thomas, Vegiopoulos, Verkest, Watson, Watson, Williams, Xenoulis, Yang, Zini, Zini, Zini, Zini, Zini, Zini   +110 more
core   +3 more sources

Efficacy and safety of once‐weekly insulins in type 2 diabetes: A systematic review and meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Once‐weekly (OW) insulins represent a promising strategy to reduce injection burden and improve adherence in type 2 diabetes management. This meta‐analysis aimed to quantify pooled effect sizes for key biological and clinical outcomes, integrating new findings from the five large trials published in 2025.
Olivier Bourron, Damien Denimal
wiley   +1 more source

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors [PDF]

, 2009
BACKGROUND: Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in ...
Berneis, K, Rini, G B, Rizvi, A A, Rizzo, M, Spinas, G A   +4 more
core   +1 more source

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay, Dayana El Chaar, Melanie Paquette, Michael Vallis, Diana Sherifali, Paul Oh, Susan Marzolini, Kaberi Dasgupta, Gillian Booth, Mike Lean, Hertzel C. Gerstein, Jordi Salas‐Salvadó, Jacqueline L. Beaudry, Christopher P. F. Marinangeli, Russell J. de Souza, Lawrence A. Leiter, Cyril W. C. Kendall, David J. A. Jenkins, John L. Sievenpiper, Laura Chiavaroli   +19 more
wiley   +1 more source